The California STEM Reporter
SEE OTHER BRANDS

Catch up with science and technology news from California

The California STEM Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The California STEM Reporter.

Press releases published on July 29, 2025

TransAlta Declares Dividends

TransAlta Declares Dividends

CALGARY, Alberta, July 29, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of TransAlta Corporation (TSX: TA) (NYSE: TAC) declared a quarterly dividend of $0.065 per common share payable on Oct. 1, 2025, to shareholders of record at the close of business …

Safetica Wins the Summer 2025 Leader Award in Data Loss Prevention from SourceForge

Safetica Wins the Summer 2025 Leader Award in Data Loss Prevention from SourceForge

Safetica is proud to be a winner of the Leader award from SourceForge, the world’s largest software reviews and comparison website. SAN JOSE, CA, UNITED STATES, July 29, 2025 /⁨EINPresswire.com⁩/ -- Safetica, the Intelligent Data Security company, …

Flex Mobile Launches First-Ever Premium Membership Model in Prepaid Wireless

Flex Mobile Launches First-Ever Premium Membership Model in Prepaid Wireless

Los Angeles, CA, July 29, 2025 (GLOBE NEWSWIRE) -- Flex Mobile has officially launched its premium membership experience for prepaid wireless customers, introducing a first-of-its-kind customer rewards program that transforms a basic phone plan into a …

Treatment.com AI Engages Market Maker

Treatment.com AI Engages Market Maker

Vancouver, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; 939: FRA) has engaged the services of Independent Trading Group ("ITG") pursuant to an agreement dated and starting …

Kneat to Announce 2025 Second-Quarter Financial Results August 5, 2025

Kneat to Announce 2025 Second-Quarter Financial Results August 5, 2025

LIMERICK, Ireland, July 29, 2025 (GLOBE NEWSWIRE) -- kneat.com, inc. (TSX: KSI) (OTC: KSIOF) (“Kneat” or the “Company”) a leader in digitizing and automating validation and quality processes, announced today that the Company will release its financial …

Rakovina Therapeutics Announces Stock Option Grants

Rakovina Therapeutics Announces Stock Option Grants

VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (FSE: 7JO0) (the “Company” or “Rakovina”), a biopharmaceutical company advancing cancer therapies through artificial intelligence (AI)-powered drug …

Axonius Acquires Medical Device Security Specialist Cynerio for More Than $100 Million to Target Healthcare Market

Axonius Acquires Medical Device Security Specialist Cynerio for More Than $100 Million to Target Healthcare Market

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- Axonius, the global leader in cyber asset intelligence, today announced that it has acquired Cynerio, a pioneer in medical device security for more than $100 million in a cash and stock transaction. The …

Silvaco to Acquire Mixel, Inc. a Provider of Low-Power, High-Performance Mixed-Signal Connectivity IP Solutions

Silvaco to Acquire Mixel, Inc. a Provider of Low-Power, High-Performance Mixed-Signal Connectivity IP Solutions

SANTA CLARA, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Silvaco Group, Inc. (“Silvaco”) (NASDAQ: SVCO), a provider of TCAD, EDA software, and SIP solutions that enable semiconductor design and digital twin modeling through AI software and innovation, today …

DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report

DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report

Châtillon, France, July 29, 2025 DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage …

DBV Technologies publie son Rapport Financier Semestriel 2025 ― Modalités de mise à disposition ou de consultation

DBV Technologies publie son Rapport Financier Semestriel 2025 ― Modalités de mise à disposition ou de consultation

Châtillon, France, le 29 juillet 2025 DBV Technologies publie son Rapport Financier Semestriel 2025 ― Modalités de mise à disposition ou de consultation DBV Technologies (Euronext : DBV – ISIN : FR0010417345 - Nasdaq : DBVT), une société biopharmaceutique …

Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025

Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025

DURHAM, N.C., July 29, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2025 …

DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results

DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results

Châtillon, France, July 29, 2025 DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, …

DBV Technologies publie ses résultats financiers du 2ème trimestre et 1er semestre 2025

DBV Technologies publie ses résultats financiers du 2ème trimestre et 1er semestre 2025

Châtillon, France, le 29 juillet 2025 DBV Technologies publie ses résultats financiers du 2ème trimestre et 1er semestre 2025 DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq Stock Market : DBVT-CUSIP : 23306J309), société biopharmaceutique …

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) – – Early PFS data show a trend favoring 30mg onvansertib dose arm vs. control arm – – Onvansertib …

Pulmonx to Present at the Canaccord Genuity 45th Annual Growth Conference

Pulmonx to Present at the Canaccord Genuity 45th Annual Growth Conference

REDWOOD CITY, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the company will be presenting at the Canaccord …

Varonis Announces Second Quarter 2025 Financial Results

Varonis Announces Second Quarter 2025 Financial Results

Annual recurring revenues grew 19% year-over-year SaaS ARR as a percentage of total ARR was approximately 69% Year-to-date cash from operations generated $89.3 million vs. $68.4 million last year Year-to-date free cash flow generated $82.7 million vs. $67. …

Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025

Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025

SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4:30pm ET on Tuesday, Aug. 5, 2025. The …

Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update

Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update

- Appointed Dr. Roger Sidhu as Chief Medical Officer - - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Announced …

EXL announces $125 million accelerated share repurchase program

EXL announces $125 million accelerated share repurchase program

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- EXL [NASDAQ: EXLS], a global data and AI company, today announced that, as part of its capital allocation program, it has entered into an accelerated share repurchase agreement (the “ASR”) with Citibank, N.A. to …

Larimar Therapeutics Announces Proposed Underwritten Public Offering

Larimar Therapeutics Announces Proposed Underwritten Public Offering

BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions